major
hurdl
surviv
lung
transplant
reject
infecti
complic
adequ
method
monitor
immun
suppress
statu
lack
evalu
quantif
torqu
teno
viru
ttv
epsteinbarr
viru
ebv
biomark
defin
net
state
immunosuppress
lungtranspl
patient
method
prospect
singlecent
studi
includ
patient
follow
year
transplant
bacteri
infect
fungal
infect
viral
respiratori
infect
vrti
cytomegaloviru
cmv
viremia
acut
reject
well
ttv
ebv
level
monitor
result
level
torqu
teno
viru
dna
increas
rapidli
transplant
like
due
immunosuppress
treatment
modest
increas
level
epsteinbarr
viru
dna
also
observ
transplant
associ
either
ttv
ebv
infecti
event
acut
reject
respect
followup
tacrolimu
main
immunosuppress
treatment
ttv
dna
level
significantli
elev
month
transplant
compar
cyclosporin
treatment
conclus
although
replic
ttv
ebv
appear
reflect
function
immun
system
depend
type
immunosuppress
treatment
quantif
ttv
ebv
biomark
limit
potenti
defin
net
state
immun
suppress
patient
endstag
lung
diseas
limit
life
expect
otherwis
accept
physic
condit
lung
transplant
may
lifesav
therapeut
option
surviv
rate
approxim
center
major
limit
factor
outcom
lung
transplant
frequent
occurr
infecti
complic
reject
transplant
organ
standard
immunosuppress
prevent
graft
reject
consist
combin
immunosuppress
drug
subvert
b
cell
current
lack
easytous
marker
accur
predict
net
effect
combin
immunosuppress
biomark
would
import
tool
manag
patient
compromis
immun
function
identifi
overor
underimmunosuppress
evalu
risk
infecti
complic
acut
reject
virus
often
view
pathogen
entiti
sever
exampl
virus
frequent
found
healthi
individu
without
caus
obviou
diseas
torqu
teno
viru
ttv
human
dna
viru
caus
asymptomat
viremia
high
preval
gener
popul
cellmedi
immun
consid
import
control
ttv
infect
accordingli
serum
level
ttvdna
increas
dramat
patient
undergon
solid
organ
transplant
presum
result
immunosuppress
epsteinbarr
viru
ebv
anoth
dna
viru
commonli
acquir
earli
life
high
preval
us
adult
establish
latent
infect
memori
b
cell
level
ebv
often
increas
blood
immunosuppress
treatment
ebv
caus
posttranspl
lymphoprolif
disord
ptld
immun
system
repress
henc
ttv
ebv
previous
suggest
surrog
marker
net
state
immunosuppress
aim
present
studi
evalu
level
ttv
ebv
relat
frequenc
infecti
event
acut
reject
time
prospect
manner
singlecent
cohort
lungtranspl
patient
patient
age
year
receiv
singl
doubl
lung
transplant
surviv
initi
postop
intens
care
period
remain
gothenburg
followup
period
januari
april
sahlgrenska
univers
hospit
transplant
centr
gothenburg
sweden
ask
particip
prospect
singlecent
cohort
studi
includ
subject
underw
followup
fu
visit
month
transplant
everi
fu
visit
whole
blood
serum
nasopharyng
sampl
nph
collect
protocol
bronchoscopi
perform
month
posttransplant
indic
base
clinic
present
bronchoalveolar
lavag
bal
sampl
collect
everi
bronchoscopi
bal
sampl
underw
direct
microscopi
earli
detect
aspergillu
hypha
cultur
bacteria
fungi
test
legionella
pneumophila
pneumocysti
jirovecii
human
cytomegaloviru
cmv
use
realtim
polymeras
chain
reaction
pcr
bal
sampl
patient
cystic
fibrosi
routin
cultur
mycobacterium
tuberculosi
atyp
mycobacteria
bacteri
fungal
cultur
test
blood
urin
sputum
perform
upon
suspicion
infect
nph
bal
sampl
everi
fu
visit
well
addit
nph
sampl
obtain
upon
suspicion
airway
infect
schedul
fu
visit
analyz
multiplex
realtim
pcr
detect
airway
pathogen
serum
sampl
obtain
pretranspl
evalu
use
ttvdna
ebvdna
quantif
quantif
ttv
ebv
fu
serum
whole
blood
sampl
use
respect
induct
therapi
consist
rabbit
antithymocyt
globulin
given
consecut
day
togeth
methylprednisolon
intraven
posttransplant
immunosuppress
includ
prednison
mgkgd
mycophenol
mofetil
mmf
gd
patient
receiv
either
oral
cyclosporin
csa
mgkg
adjust
maintain
serum
level
ngml
tacrolimu
tac
mgkg
given
oral
divid
dose
daili
adjust
maintain
serum
level
ngml
choic
csa
tac
made
base
clinic
present
patient
previous
treat
tac
patient
cystic
fibrosi
given
tac
also
prefer
tac
recipi
younger
dosag
immunosuppress
gradual
lower
fu
chang
immunosuppress
therapi
base
clinic
present
four
patient
either
underw
retransplant
previou
immunosuppress
treatment
due
autoimmun
condit
given
nonstandard
immunosuppress
therapi
base
previou
exposur
immunosuppress
drug
patient
receiv
combin
mg
sulfametoxazol
mg
trimetoprim
thrice
weekli
prevent
pneumocysti
jirovecii
infect
patient
seroposit
cmv
pretranspl
evalu
given
valganciclovir
dose
mg
daili
month
patient
seroneg
cmv
pretranspl
organ
donor
test
posit
ie
cmv
mismatch
given
treatment
month
bacteri
infect
defin
posit
bacteri
cultur
conjunct
symptom
clinic
infect
absenc
posit
cultur
symptom
consist
bacteri
infect
treat
antibiot
fungal
infect
defin
signific
presenc
fungi
cultur
steril
locat
conjunct
symptom
infect
accord
european
organ
research
treatment
cancer
eortc
criteria
vrti
mycoplasma
pneumonia
infect
defin
detect
pathogen
multiplex
realtim
pcr
nph
bal
cmv
viremia
defin
elev
level
cmvdna
prompt
antivir
therapi
cmvseroneg
recipi
consid
viremia
cmvdna
detect
wherea
recipi
seroposit
cmv
prior
transplant
consid
cmv
viremia
level
copiesml
distinguish
milder
infect
sever
infecti
event
subgroup
event
requir
initi
intraven
antimicrobi
antibacteri
antivir
antifung
therapi
defin
sever
acut
reject
defin
either
lung
biopsi
show
reject
ishlt
grade
higher
absenc
biopsi
physic
increas
need
oxygen
radiolog
find
progress
infiltr
without
sign
infect
consist
acut
reject
follow
prompt
respons
highdos
gd
consecut
day
corticosteroid
therapi
methylprednisolon
nucleic
acid
isol
perform
magna
pure
lc
total
nucleic
acid
dna
isol
kit
serum
ttv
whole
blood
ebv
cmv
use
standard
protocol
accord
instruct
roch
diagnost
mannheim
germani
inputoutput
volum
set
sampl
elut
extract
buffer
ttvdna
level
determin
use
realtim
pcr
system
appli
biosystem
foster
citi
ca
pcr
reaction
contain
extract
total
nucleic
acid
univers
master
mix
appli
biosystem
foster
citi
ca
forward
revers
primer
respect
bhq
hydrolysi
probe
rnasefre
reaction
condit
minut
minut
prior
cycl
second
second
assay
rang
determin
serial
dilut
plasmid
insert
synthes
sequenc
match
ttv
pcr
product
quantif
obtain
plot
ct
valu
cmvand
ebvdna
level
determin
use
method
describ
previous
minor
modif
primer
probe
sequenc
list
supplementari
tabl
ebv
cmv
quantif
control
sampl
consist
unrel
phocin
herpesviru
includ
prior
nucleic
acid
extract
ttv
load
quantifi
droplet
digit
pcr
system
use
ddpcr
supermix
probe
dutp
biorad
hercul
ca
primer
probe
concentr
final
reaction
nm
respect
pcr
condit
minut
follow
minut
second
minut
total
cycl
final
step
minut
overnight
incub
droplet
fluoresc
signal
determin
data
analysi
done
use
biorad
quanta
soft
analysi
softwar
isol
dna
rna
analyz
use
multiplex
realtim
pcr
system
design
detect
adenoviru
bocaviru
chlamydophila
pneumonia
human
coronaviru
human
enteroviru
human
metapneumoviru
human
rhinoviru
influenza
viru
influenza
b
viru
mycoplasma
pneumonia
parainfluenzaviru
respiratori
syncyti
viru
pcr
set
list
primer
probe
describ
previous
comparison
group
level
numer
variabl
perform
use
mannwhitney
u
test
pearson
correl
linear
regress
use
evalu
relationship
realtim
pcr
ddpcr
measur
cox
regress
ttv
ebv
timedepend
covari
use
analyz
relationship
biomark
outcom
vrti
fungal
infect
bacteri
infect
cmv
viremia
infecti
event
patient
treat
cluster
handl
multipl
infect
occur
singl
individu
univari
logist
regress
use
period
month
outcom
vrti
fungal
infect
bacteri
infect
cmv
viremia
infect
acut
reject
predictor
age
treatment
cmv
mismatch
log
ttv
begin
period
log
ebv
begin
period
p
valu
consid
signific
r
softwar
version
r
core
team
r
foundat
statist
comput
vienna
austria
http
wwwrprojectorg
use
statist
analys
except
pearson
correl
analysi
perform
use
graphpad
prism
softwar
graphpad
softwar
inc
san
diego
ca
studi
approv
region
ethic
review
board
gothenburg
dnr
subject
provid
written
oral
consent
particip
total
lung
transplant
recipi
includ
studi
still
aliv
month
transplant
detail
patient
descript
outlin
tabl
blood
bal
nasopharyng
sampl
nph
collect
longitudin
followup
fu
visit
month
postlung
transplant
ltx
n
includ
pretranspl
sampl
total
nucleic
acid
content
isol
serum
whole
blood
sampl
analyz
ttv
ebv
cmvdna
load
realtim
pcr
total
nucleic
acid
content
isol
nph
bal
sampl
analyz
respiratori
pathogen
use
multiplex
realtim
pcr
major
patient
detect
ttvdna
level
transplant
preltx
level
subsequ
increas
peak
reach
month
postltx
level
gradual
decreas
figur
mean
ttvdna
level
respect
time
period
month
postltx
month
postltx
month
postltx
month
postltx
respect
convers
major
patient
detect
ebvdna
prior
transplant
determin
serum
month
postltx
peak
mean
ebvdna
level
observ
decreas
alreadi
month
postltx
thereaft
remain
rel
constant
level
determin
whole
blood
figur
mean
ebvdna
level
respect
time
period
month
postltx
month
postltx
month
postltx
month
postltx
respect
overal
fewer
patient
detect
level
ebvdna
compar
ttvdna
figur
although
individu
ttvdna
level
vari
major
patient
detect
level
across
entir
fu
period
comparison
minor
patient
detect
level
ebvdna
longer
consecut
period
larg
fraction
ebvdna
level
level
quantif
loq
given
time
point
fu
figur
three
patient
develop
suspect
ptld
case
biopsyverifi
revers
upon
modif
immunosuppress
detail
individu
ttvand
ebvdna
level
kinet
patient
includ
inform
regard
infecti
event
acut
reject
display
supplementari
figur
comparison
ttvand
ebvdna
level
lung
transplant
recipi
receiv
either
tacrolimusor
cyclosporinebas
therapi
reveal
cyclosporinetr
patient
significantli
lower
ttvdna
level
serum
month
postltx
onward
compar
tacrolimustr
patient
figur
signific
differ
ebvdna
level
whole
blood
tacrolimusand
cyclosporinetr
patient
time
point
fu
figur
fu
divid
period
denot
defin
month
transplant
period
interv
chosen
distinguish
initi
phase
intens
immunosuppress
later
period
immunosuppress
therapi
gradual
lower
viral
infect
vrti
common
first
month
bacteri
fungal
infect
evenli
distribut
throughout
period
cmv
viremia
occur
higher
frequenc
month
ltx
discontinu
prophylact
ganciclovir
treatment
tabl
event
acut
reject
common
first
postop
month
decreas
time
figur
episod
acut
reject
biopsyverifi
frequenc
infecti
event
figur
tabl
compar
mean
ttvdna
ebvdna
level
period
total
fu
period
respect
statist
signific
associ
found
logist
regress
log
ttvdna
log
ebvdna
level
begin
period
predict
infecti
event
period
supplementari
tabl
next
perform
cox
regress
analysi
establish
ttvor
ebvdna
level
associ
either
viral
tabl
signific
associ
found
use
criterion
compar
factor
relev
infect
acut
reject
use
logist
regress
found
age
cmv
mismatch
domin
immunosuppress
treatment
predict
outcom
period
denot
supplementari
tabl
acut
reject
event
ar
occur
within
first
month
postltx
figur
logist
regress
initi
ttvdna
ebvdna
period
respect
predict
whether
acut
reject
event
would
occur
period
data
shown
previou
studi
describ
higher
mean
ttvdna
level
lung
transplant
patient
report
order
verifi
realtim
pcr
result
ttvdna
level
patient
mean
ttvdna
level
period
assess
digit
droplet
pcr
ddpcr
ttvdna
level
underestim
realtim
pcr
sampl
overal
level
obtain
realtim
pcr
correl
well
result
obtain
ddpcr
pearson
r
p
supplementari
tabl
ttv
ebv
propos
biomark
reflect
function
immun
system
ltx
prospect
studi
evalu
serial
sampl
ttv
ebv
care
record
infecti
reject
event
fu
period
month
found
associ
biomark
risk
complic
found
ttvdna
level
increas
rapidli
month
ltx
level
alreadi
markedli
elev
presum
due
ablat
function
effector
cell
immun
system
normal
control
ttv
infect
month
postltx
mean
ttvdna
level
peak
gradual
declin
reflect
gradual
moder
immunosuppress
therapi
interestingli
ttvdna
level
lower
patient
receiv
cyclosporin
treatment
possibl
mirror
differ
immun
modulatori
mechan
cyclosporin
compar
tacrolimu
et
al
previous
suggest
might
due
cyclosporin
less
effici
immunosuppress
howev
found
associ
type
immunosuppress
regimen
acut
reject
event
would
indic
differ
net
immunosuppress
effect
recent
ttvdna
associ
chronic
lung
allograft
dysfunct
lung
transplant
studi
includ
outcom
possibl
observ
higher
mean
ttvdna
level
studi
could
explain
differ
induct
therapi
distribut
respect
immunosuppress
regimen
exampl
studi
et
al
type
induct
therapi
defin
patient
treat
cyclosporin
evid
ttv
replic
depend
type
induct
therapi
appear
reflect
chang
lymphocyt
concentr
howev
durat
brief
level
ttv
recov
present
studi
ttv
viral
load
determin
serum
sampl
wherea
plasma
use
previou
studi
howev
knowledg
appar
reason
variat
ttvdna
load
depend
whether
plasma
serum
use
analysi
compar
result
regard
ttv
level
differ
transplant
center
vital
reliabl
quantifi
concentr
ttvdna
standard
manner
shown
realtim
pcr
method
adequ
compar
ddpcr
method
consid
reliabl
method
accur
quantif
nonetheless
realtim
pcr
prone
interlaboratori
differ
util
ddpcr
quantif
suggest
circumv
problem
facilit
direct
comparison
result
center
digit
droplet
pcr
depend
partit
master
mix
follow
end
point
pcr
quantit
determin
use
poisson
statist
gener
result
depend
relat
standard
curv
therefor
exhibit
lower
variabl
laboratori
howev
ddpcr
assay
still
depend
amplif
specif
target
sequenc
depend
design
primer
probe
target
sequenc
vari
recent
work
shown
viral
dna
plasma
sampl
larg
extent
free
associ
viral
particl
also
subject
variou
degre
degrad
influenc
result
depend
amplicon
length
determin
pcrassay
design
thu
standard
entir
assay
includ
primer
probe
design
use
intern
standard
assess
commut
refer
materi
need
direct
comparison
interlaboratori
result
made
absolut
confid
even
use
ddpcr
remain
clarifi
cell
type
ttv
replic
occur
cell
cell
appear
import
control
infect
wherea
ebv
resid
within
bcell
pool
control
cell
work
show
choic
calcineurin
inhibitor
affect
ttvbut
ebvdna
level
possibl
reflect
separ
mechan
viral
replic
rather
mere
ablat
tcell
pool
choic
immunosuppress
regimen
made
discret
treat
physician
find
interpret
caution
warrant
investig
studi
infecti
event
defin
symptom
prompt
antimicrobi
therapi
also
case
without
posit
cultur
bacteri
fungal
infect
simpli
detect
potenti
pathogen
pcr
vrti
cmv
attempt
focu
sever
infecti
event
subgroup
analysi
event
requir
intraven
therapi
made
also
analysi
fail
reveal
signific
associ
ttvor
ebvdna
level
infecti
event
howev
proper
valid
score
system
grade
sever
infecti
complic
use
studi
exclud
definit
caus
underestim
sever
complic
studi
use
proper
grade
event
need
ebv
previous
suggest
surrog
marker
immunosuppress
associ
elev
ebvdna
level
reduc
incid
acut
reject
lung
transplant
observ
addit
ebvdna
safe
use
trigger
reduct
immunosuppress
late
lung
transplant
found
associ
shorter
time
develop
infecti
complic
solid
tumor
ptld
found
associ
ebvdna
acut
reject
time
fu
direct
comparison
could
howev
hamper
fact
ebvdna
analyz
studi
ebvencod
rna
earlier
studi
present
studi
mean
ebvdna
level
increas
markedli
ttvdna
level
transplant
even
though
ebvspecif
cell
like
subvert
immunosuppress
therapi
seropreval
preltx
number
patient
posit
ebvdna
time
fu
compar
previou
studi
one
possibl
caveat
determin
ebv
dna
load
use
valgangciclovir
prevent
reactiv
primari
infect
cmv
patient
receiv
month
valgangciclovir
treatment
initi
ltx
studi
show
valgangciclovir
treatment
reduc
ebv
load
may
affect
result
studi
conclus
ttvbut
ebvdna
load
appear
reflect
function
immun
system
lung
transplant
depend
type
immunosuppress
treatment
howev
found
associ
either
ttvor
ebvdna
load
infecti
event
acut
reject
suggest
limit
clinic
applic
biomark
predict
shortterm
outcom
relat
net
state
immunosuppress
studi
warrant
defin
effect
immunomodul
ttv
ebv
replic
relat
variou
immunosuppress
regimen
supplementari
materi
avail
open
forum
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
